Micromet To Present Clinical Update For BiTE Antibody MT103/MEDI-538 At The International Conference On Malignant Lymphomas

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.

More: continued here

Filed under: Lymphoma / Leukemia on June 1st, 2008